• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
Post-Pandemic School Policies: Attendance and Health Guidelines

Post-Pandemic School Policies: Attendance and Health Guidelines

by Oceanit | Mar 17, 2025 | Education, Future, National News

Post-Pandemic School Policies: Attendance and Health Guidelines In the wake of the COVID-19 pandemic, U.S. schools have implemented new policies to ensure the safety and well-being of students and staff. These measures, guided by recommendations from the Centers for...
Latest Research on Long COVID and Its Long-Term Effects on COVID-19 Survivors

Latest Research on Long COVID and Its Long-Term Effects on COVID-19 Survivors

by Oceanit | Mar 14, 2025 | Future, General

Latest Research on Long COVID and Its Long-Term Effects on COVID-19 Survivors As the world continues to navigate the aftermath of the COVID-19 pandemic, long COVID has emerged as a significant public health concern. Recent studies and reports shed light on the...
Envisioning Public Health in 2045: Lessons from COVID-19, mRNA Vaccines, and Pandemic Responses

Envisioning Public Health in 2045: Lessons from COVID-19, mRNA Vaccines, and Pandemic Responses

by Oceanit | Mar 13, 2025 | Future, General

Envisioning Public Health in 2045: Lessons from COVID-19, mRNA Vaccines, and Pandemic Responses The COVID-19 pandemic has indelibly transformed the landscape of public health, catalyzing innovations and strategies that will shape our approach to health crises over the...
Staying Ahead of Evolving COVID-19 Variants: How Scientists Track SARS-CoV-2 Mutations​

Staying Ahead of Evolving COVID-19 Variants: How Scientists Track SARS-CoV-2 Mutations​

by Oceanit | Mar 13, 2025 | Education, Future

Staying Ahead of Evolving COVID-19 Variants: How Scientists Track SARS-CoV-2 Mutations​ The rapid evolution of SARS-CoV-2, the virus responsible for COVID-19, has continually challenged global public health efforts. A recent article from NPR delves into how scientists...
Seasonal Viral Infections Decline: Understanding the Quad-demic Cycle of Flu, COVID-19, and RSV

Seasonal Viral Infections Decline: Understanding the Quad-demic Cycle of Flu, COVID-19, and RSV

by Oceanit | Mar 13, 2025 | Future, General

Seasonal Viral Infections Decline: Understanding the Quad-demic Cycle of Flu, COVID-19, and RSV As of March 13, 2025, the United States is witnessing a notable decline in seasonal viral infections, particularly influenza (flu), COVID-19, and respiratory syncytial...
COVID-19 Variants: Evolution Pace, Booster Shots, and Infectiousness

COVID-19 Variants: Evolution Pace, Booster Shots, and Infectiousness

by Oceanit | Mar 12, 2025 | Future, General

COVID-19 Variants: Evolution Pace, Booster Shots, and Infectiousness Since its emergence, SARS-CoV-2, the virus responsible for COVID-19, has undergone continuous evolution, leading to the development of multiple variants. Understanding the pace at which these...
« Older Entries
Next Entries »

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
  • Privacy Policy